<code id='F664994E7E'></code><style id='F664994E7E'></style>
    • <acronym id='F664994E7E'></acronym>
      <center id='F664994E7E'><center id='F664994E7E'><tfoot id='F664994E7E'></tfoot></center><abbr id='F664994E7E'><dir id='F664994E7E'><tfoot id='F664994E7E'></tfoot><noframes id='F664994E7E'>

    • <optgroup id='F664994E7E'><strike id='F664994E7E'><sup id='F664994E7E'></sup></strike><code id='F664994E7E'></code></optgroup>
        1. <b id='F664994E7E'><label id='F664994E7E'><select id='F664994E7E'><dt id='F664994E7E'><span id='F664994E7E'></span></dt></select></label></b><u id='F664994E7E'></u>
          <i id='F664994E7E'><strike id='F664994E7E'><tt id='F664994E7E'><pre id='F664994E7E'></pre></tt></strike></i>

          hotspot

          hotspot

          author:leisure time    Page View:354
          UnitedHealth Group
          UnitedHealth Group’s Optum will pay $3.3 billion total for the home health giant Amedisys. Jim Mone/AP

          Home health and hospice chain Amedisys has chosen a new corporate owner.

          Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

          advertisement

          Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Wildfire smoke exposes gaps in outdoor worker protections
          Wildfire smoke exposes gaps in outdoor worker protections

          ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

          read more
          Novo Holdings to buy drug manufacturer Catalent in $16.5B deal
          Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

          CarstenSnejbjerg/BloombergLONDON—TheinvestmentarmofNovoNordisk’sparentfoundationisbuyingdrugmanufact

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          Readout Newsletter: Amgen, Regeneron, BGI Group and more

          KristofferTripplaar/SipaviaAPWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup toget